Advertisement

Medical Oncology

, 36:25 | Cite as

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine

  • Takahiro Kamiya
  • Tomonori NakazatoEmail author
Letter to the Editor
  • 37 Downloads

Dear Editor,

The myelodysplastic syndromes (MDS) is a representative of myeloid clonal blood diseases with relatively heterogeneous spectrums of symptoms. The major clinical problem in MDS are morbidities caused by cytopenia or transition to acute myeloid leukemia (AML). The current clinical management of MDS focuses on assessing disease risk at diagnosis by assaying clinical and patient characteristics and using established prognostic scoring systems to estimate survival and risk of evolution to AML. Several prognostic scoring systems have been developed and validated, but the most widely used systems include the International Prognostic Scoring System (IPSS) and the Revised International Prognostic Scoring System (IPSS-R). Because the IPSS is limited in its ability to identify poor prognosis lower-risk patients, a prognostic scoring system specifically for lower-risk MDS patients (LR-PSS) was also developed at MD Anderson cancer center [1]. Recently, several studies demonstrated...

Notes

Funding

No specific funding was obtained to support the conduct of this study.

Compliance with ethical standards

Conflict of interest

All authors have no potential conflicts of interest to report.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patients. The study was approved by the Ethics Committee of Yokohama Municipal Citizen’s Hospital.

References

  1. 1.
    Garcia-ManeroG ShanJ, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2007;22(3):538–43.CrossRefGoogle Scholar
  2. 2.
    Duong VH, Padron E, Al Ali NH, et al. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Ann Hematol. 2018;97(2):247–54.CrossRefGoogle Scholar
  3. 3.
    Knipp S, Strupp C, Gattermann N, et al. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res. 2008;32(1):33–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of HematologyYokohama Municipal Citizen’s HospitalYokohamaJapan

Personalised recommendations